ARCOMA Stock Overview
Develops, produces, and provides radiology solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arcoma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 10.75 |
| 52 Week High | SEK 18.30 |
| 52 Week Low | SEK 7.60 |
| Beta | 0.91 |
| 1 Month Change | 2.87% |
| 3 Month Change | -25.86% |
| 1 Year Change | 35.22% |
| 3 Year Change | -19.78% |
| 5 Year Change | -48.81% |
| Change since IPO | -21.53% |
Recent News & Updates
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop
Nov 09
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business
Aug 22At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?
Aug 07Recent updates
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop
Nov 09Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business
Aug 22At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?
Aug 07Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?
Apr 26Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Feb 06Is Arcoma (STO:ARCOMA) A Risky Investment?
Jan 15We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt
Sep 11Is Arcoma (STO:ARCOMA) Using Too Much Debt?
Jun 08Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Apr 27Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?
Dec 22Is Arcoma (STO:ARCOMA) Using Too Much Debt?
May 03These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively
Oct 28Is Arcoma (STO:ARCOMA) A Risky Investment?
Mar 17Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Feb 04Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?
Jan 14
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 12These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well
Dec 17Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)
Nov 21Shareholder Returns
| ARCOMA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.9% | 0.4% | 0.6% |
| 1Y | 35.2% | -8.8% | 4.2% |
Return vs Industry: ARCOMA exceeded the Swedish Medical Equipment industry which returned -8.6% over the past year.
Return vs Market: ARCOMA exceeded the Swedish Market which returned 4.5% over the past year.
Price Volatility
| ARCOMA volatility | |
|---|---|
| ARCOMA Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ARCOMA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ARCOMA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 32 | Mattias Leire | www.arcoma.se |
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners.
Arcoma AB Fundamentals Summary
| ARCOMA fundamental statistics | |
|---|---|
| Market cap | SEK 141.74m |
| Earnings (TTM) | SEK 12.98m |
| Revenue (TTM) | SEK 171.33m |
10.9x
P/E Ratio0.8x
P/S RatioIs ARCOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCOMA income statement (TTM) | |
|---|---|
| Revenue | SEK 171.33m |
| Cost of Revenue | SEK 105.73m |
| Gross Profit | SEK 65.60m |
| Other Expenses | SEK 52.62m |
| Earnings | SEK 12.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 38.29% |
| Net Profit Margin | 7.58% |
| Debt/Equity Ratio | 0% |
How did ARCOMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:08 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arcoma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hjalmar Jernstrom | Penser Access |